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Abbreviations and symbols:
AK  Actinic keratosis 
ALA  Aminolevulinic acid 
BAT  Brain adjacent to tumor 
BCC  Basal cell carcinoma 
CCD Charge coupled device 
H&E Hematoxylin and eosin 
i.p. intraperitoneal 
LED Light emitting diode 
MAL  Methyl aminolevulinate 
PDT  Photodynamic therapy 
PpIX  Protoporphyrin IX 
SD Standard deviation 
SEM Standard error of the mean 
2  Singlet oxygen
I   Light fluence rate (mW cmÞ2)
E Irradiance (mW cmÞ2)
P Radiant power (mW) 
Pa Absorption coefficient (cmÞ1)
sPc Reduced scattering coefficient (cm
Þ1)
G Light penetration depth (mm) 
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Glossary:
Action spectrum Spectrum describing for which wavelengths a certain process will 
take place. 
Apoptosis Cell death controlled actively by a “suicide” program. 
Carcinoma Malignant tumor originating from epithelial tissues 
Cytoreduction Decrease in the number of (tumor) cells. 
Dysplasia A pre-cancerous change. 
Endogenous Originating within the organism or cell. 
Endothelium The epithelium lining the interior surface of blood vessels. 
Exogenous Originating outside the organism. 
Glioma Tumor originating from glial cells, the major non-neuronal cell type in the 
central nervous system.  
Gray matter Regions of brain and spinal chord consisting of mainly neurons, cell 
bodies, and capillaries. 
Indwelling  Placed or implanted within the body, as a catheter or electrode. 
Inoculation  Introduction (of for instance tumor cells) into a host. 
Necrosis Death of cells or tissues as a result of external damage. 
Neutrophils Subtype of white blood cells that is much involved in the acute phase 
of inflammation. 
Occlusive dressing An air- and watertight dressing. 
Photobleaching Degradation of a dye as a result of light exposure. 
Pro-drug An inactive substance that is converted to a drug within the body. 
Quantum yield The probability that an excitation will lead to a certain process.  
Squamous cell carcinoma in situ (or Bowen’s disease) An early noninvasive stage of 
cancer originating from the squamous cells in skin or mucosa.
Systemic application Distribution of a substance throughout the whole body 
Thermal penetration depth Parameter related to the range of a local temperature 
aberration in a tissue. (Definition in publication IV.) 
Turbid Cloudy or hazy. 
White matter Regions of brain and spinal chord consisting mainly of neural fibers. 
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1 Introduction 
Photodynamic therapy (PDT) is mediated by a photosensitizer—a substance able to 
absorb energy from light and subsequently transfer it to oxygen, which in its turn
deposits the energy as damage to biological matter. Consequently, the treatment
involves both distribution of a drug (the photosensitizer) and distribution of light 
using an adequate light source. The knowledge of photosensitizing drugs is ancient, 
but it is mainly throughout the last 30 years that PDT has been developed as a 
treatment modality for cancer (Ackroyd et al. 2001). A range of photosensitizers are
currently approved for various indications (Figure 1).
1.1 The fundamentals of PDT 
A good photosensitizer must absorb light efficiently. A molecule absorbs light by 
being excited to a different state, gaining the energy of one photon (Einstein 1912). 
Molecules with chains of conjugated bonds can have electron states matching the 
photon energy of visible or near infrared light. The skeleton of most sensitizers used 
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Figure 1: Chemical structure of photosensitizers approved by medical authorities for
treatment of (a) esophageal dysplasia, (b) head and neck cancer, (c and d) actinic
keratosis, (d) non melanotic skin cancer, and (f) wet macular degeneration. The
prodrugs (c) and (d) are synthesized into (e) intracellularly.
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in PDT is the porphin (Figure 2), which consists of four 
pyrrole rings joined to a ring structure with a cyclic, conju-
gated system of 18 S-electrons. This system has electron states 
matching visible light. Molecules in excited electron states 
may participate in chemical reactions damaging biomolecules
that are vital for the function of a cell. Generally speaking, such reactions do not
depend on the presence of oxygen, but photodynamic effect is defined as oxygen-
dependent reactions exclusively (Blum 1941). 
N
NH
N
NH
Figure 2: Porphin
Most states excited by photoexcitation are short-lived (a few nanoseconds), and 
will return to the ground state by fluorescence or heat-transfer before interaction 
with other molecules can occur. For most molecules, both the ground state and the 
first excited state are so-called singlet states, with all electrons paired so that the only
option for the molecule’s net spin is zero. In general, but almost exclusively in ex-
cited states, molecules can also be in triplet states. Two electrons are then unpaired, 
leaving three options for the net spin component: +1, zero, or Þ1 (as each electron 
has spin +½ or Þ½). Processes not conserving the net spin, such as transfer from an 
excited triplet state to a singlet ground state, are relatively unlikely. This means that
excited triplet states can be sufficiently stable to allow interaction with other mole-
cules. Photodynamic effect depends on a high quantum yield for formation of such 
metastable excited triplet states after photoexcitation (Figure 3 a and b). For good
photosensitizers this quantum yield is typically 0.2–0.9 (Redmond & Gamlin 1999). 
The reactions dominating for most sensitizers used in PDT are by the so-called 
type II pathway, where the excited triplet state (3PS*) interacts with molecular
oxygen by energy transfer. The sensitizer returns to the singlet ground state (1PS),
and oxygen is excited to the reactive species singlet oxygen (1O2) (Figure 3c)
(Kawaoka et al. 1967). As illustrated in Figure 3c, oxygen’s unique feature as a 
molecule with a triplet ground state (3O2) makes this a spin-conserving process, 
which is more efficient than non spin-conserving reactions with other molecules.
Good photosensitizers typically have quantum yields for 1O2 formation in the range
0.1–0.8 (Redmond & Gamlin 1999). Singlet oxygen can return to the ground state
by phosphorescence. This is a very slow process, so in non-gaseous environments 
1PS(ĹĻ) + hQ ĺ 1PS*(ĹĻ) (a)
1PS*(ĹĻ) ĺ 3PS*(ĻĻ) (b)
3PS*(ĻĻ) + 3O2 (ĹĹ) ĺ 1PS(ĹĻ) + 1O2*(ĹĻ) (c)
Figure 3: (a) Photoexcitation of photosensitizer (PS) to excited singlet state. As shown
by the arrows both states have paired electrons. (b) Intersystem crossing to a metasta-
ble excited triple state that has unpaired electrons with parallel spins. (c) The type II
reaction, were the metastable triple state excites ground state triplet oxygen into singlet
oxygen by energy transfer. 
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participation in chemical reactions is much more likely. 1O2 reacts with a variety of 
biomolecules, and these reactions are so efficient that the intracellular lifetime of 1O2
is in the nanosecond range, corresponding to a radius of action around 0.01 microns
(Moan & Berg 1991, Niedre et al. 2002). This means that most of the initially 
induced damage is restricted to the subcellular compartment containing the photo-
sensitizer. Consequently, when distributing the photosensitizer, intracellular localiza-
tion may be as important as concentration. Reported estimates of the number of 1O2
molecules necessary to kill a cell has varied with three orders of magnitude from 108
to 1011 in different experimental setups (Niedre et al. 2005). There is some uncer-
tainty in these estimates, but the vast range reflects the fact that PDT inactivation is 
not necessarily a simple matter of acute lethal 1O2 damage. A thorough understand-
ing of the biology is necessary to describe the PDT-induced damage, which may be 
affected significantly by factors such as cell signaling pathways, programmed cell 
death, indirect vascular damage, and effects of the host’s immune system (Dougherty
et al. 1998). 
Photochemical reactions can also be mediated by the type I pathway, where
(unlike Figure 3c) the excited triplet state interacts with a substrate by electron or 
proton transfer. This leads to generation of cytotoxic agents, including reactive 
oxygen species other than 1O2. The prevailing hypothesis is that 1O2 is the important 
cytotoxin in PDT (Weishaupt et al. 1976, Fuchs & Thiele 1998), although additional
effects of type I reactions can not be discounted. It has been reported that reactive 
oxygen species other than 1O2 can dominate for certain sensitizers and environments 
(Vakrat-Haglili et al. 2005). However, for protoporphyrin IX mediated PDT Þ the 
topic of this thesis Þ it has recently been shown by direct in vivo measurements of
1O2 phosphorescence that the PDT-induced damage is directly related to the amount
of 1O2 produced (Niedre et al. 2005). 
1.2 Drug distribution
Most photosensitizers used in PDT are applied systemically by intravenous injection. 
Different photosensitizers, formulations and application schemes can target different 
tissues. Typically, short drug–light intervals (down to minutes) lead to vascular
damage, while direct damage to tumor cells can be achieved using longer drug–light
intervals (up to several days). The localization is also strongly dependant on the 
physiochemical properties of the drug, and in some cases of its ability to bind to 
specific targets in endothelial or tumor cells (Chen et al. 2006). The photosensitizer, 
the drug administration, and the drug–light interval should ideally be optimized to 
achieve sufficiently high accumulation of photosensitizer in the target tissue and 
acceptably low accumulation in the surrounding normal tissues. Properties of tumors
that make selective photosensitizer uptake possible include: a leaky vascular system,
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poor lymph drainage, large extracellular volume, high amounts of collagen, de-
creased pH, and deviating cellular receptors and uptake mechanisms (Dougherty et 
al. 1998). Still, the selectivity achieved with systemic photosensitizers is often not
better than around a factor of two (Moore et al. 1997). A major exception is brain 
tumors, where at least one order of magnitude of selectivity can be achieved for 
photosensitizers that to a low degree penetrate the blood–brain barrier (Chopp et al.
1996, Obwegeser et al. 1998, Lobel et al. 2001). Maximum selectivity is always 
desirable, but the degree of damage that can be tolerated in the surrounding normal
tissues varies substantially. In some cases—like for m-tetrahydroxyphenylchlorin
mediated PDT for head and neck cancer—severe necrosis following PDT can heal up 
well without unacceptable scarring (Hopper et al. 2004). In other areas—like the 
esophagus, brain, or retina—damage to normal tissue can be dangerous. 
1.2.1 Porphyrin precursor mediated PDT 
As an alternative to direct administration of a photosensitizer, it is possible to make
an organism photosensitive by administering drugs that are not photosensitizers 
themselves. The naturally occurring compound aminolevulinic acid (ALA) can be
used as a pro-drug to induce accumulation of endogenous porphyrins that act as 
photosensitizers (Peng et al. 1987, Malik & Lugaci 1987). The porphyrins are syn-
thesized intracellularly by the heme synthesis pathway as shown in Figure 4. The rate
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Figure 4: The heme biosynthesis that takes place in eukaryotic cells. Excess of ALA will lead to
accumulation of PpIX, the immediate precursor to heme. For several neoplastic cell types this 
accumulation is enhanced due to increased activity of porphobilinogen deaminase, decreased
activity of ferrochelatase, or increased transport past the mitochondrial membrane due to
abundant expression of the peripheral benzodiazepine receptor (Collaud et al. 2004).
INTRODUCTION 5
limiting step of this pathway is the synthesis of ALA. If an excess of ALA is supplied 
exogenously, the insertion of iron into the porphyrin ring to form heme becomes the 
rate limiting step. This leads to accumulation of the photosensitizer protoporphyrin 
IX (PpIX). 
Systemic application of ALA is possible and is used for experimental therapy of
various indications including esophageal dysplasia (Pech et al. 2005), but local drug
application with topical formulations is most common. Local drug application is a 
great advantage as it eliminates the obvious problems associated with general photo-
sensitization of the whole patient. Topical ALA PDT was introduced by Kennedy et
al. in 1990. Since then, a variety of skin disorders have been treated using ALA or 
other porphyrin precursors. The transport of ALA through tissues and into cells has
been reported to be suboptimal (Peng et al. 1995, Martin et al. 1995, Wolf & Kerl
1995). ALA esters, which are more lipophilic porphyrin precursors, were introduced
to overcome this limitation and to improve the bioavailability (Peng et al. 1996, 
Kloek & Beijersbergen 1996). Differences between ALA and its esters have been 
shown for a variety of key issues, including uptake and porphyrin production in cells 
(Gaullier et al. 1997, Rud et al. 2000, Gederaas et al. 2001, Perotti et al. 2004), 
transport through tissues (de Rosa & Bentley 2000, Bigelow et al. 2001, van den 
Akker et al. 2003), ability to induce porphyrin production in tissues (Fritsch et al.
1998, Lange et al. 1999, Perotti et al. 2002), effects of drug formulations (Casas et 
al. 2001, Lopez et al. 2004), systemic uptake (Moan et al. 2001), and pain felt 
during PDT (Wiegell et al. 2003, Kasche et al. 2006). 
A vide variety of tissues are photosensitized by porphyrin precursors, but certain
tissue types have a low ability to produce endogenous porphyrins. These include 
cases where damage would be critical such as connective, muscle, and brain tissues
(Fukuda et al. 1992). This represents a useful selectivity enhancement, but it can also
limit the efficacy of the treatment for certain tumors that has a low ability to pro-
duce endogenous porphyrins (Morgan et al. 2004). Successful indications for por-
a   b 
Figure 5: Porphyrin fluorescence from cancer in (a) bladder mucosa (Berg et al. 2005)
and (b) skin after local application of hexaminolevulinate and methyl aminolevulinate,
respectively.
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phyrin precursor mediated PDT mostly include premalignant lesions or low-grade
non-invasive tumor types. Porphyrin precursors can also be of diagnostic value as a 
contrast agent, utilizing PpIX’s characteristic fluorescence (Figure 5). This is most 
widely used in urology, where hexaminolevulinate (the hexyl ester of ALA) is ap-
proved for fluorescence-guided detection of bladder cancer (Jocham et al. 2005). For 
malignant brain tumors the usefulness of ALA-based, fluorescence-guided resection
has recently been demonstrated in an extensive phase III clinical trial (Stummer et al.
2006).
1.3 Light distribution
The targeted application and limited penetration of light makes PDT a local treat-
ment modality. Transport of light through tissue is limited by absorption and scatter-
ing. These processes result in an approximately exponential decrease in the fluence
rate (i.e., the light intensity inside the tissue) as the light penetrates tissue. For an 
infinite planar geometry, the light penetration depth (G) is the distance at which the 
fluence rate has been reduced by a factor e (§ 0.37) (Star 1997). As shown in Figure
6a, the light penetration depth is strongly dependent on wavelength. Most porphin 
based photosensitizers have their absorption maximum in the blue region around 
400 nm, but the hemoglobin found in most tissues limits the penetration depth of
blue light to about a tenth of a millimeter. The photosensitizers most commonly used 
in PDT (Figure 1, page 1) absorb also in the red region, where the penetration depth 
is 2–3 mm for most tissues (Cheong 1995). The best light penetration is found in the
near infrared region from about 750 to 850 nm where penetration depths can reach 
5–6 mm. The sensitizers motexafin lutetium (732 nm) and Pd-bacteriopheophorbide
(TOOKAD®) (762 nm) absorb in this region and are used for experimental PDT of
prostate cancer (Zhu et al. 2005, Weersink et al. 2005). 
a
(cm
-
1 )
1
10
100
Wavelength (nm)
400 600 800 1000
(m
m)
0
2
4
G
Pa
Ps'
    b
Figure 6: a) Absorption coefficients (Pa) and reduced scattering coefficients ( )
typically found in tissue, based on spectra published by Jacques et al. (1998). The
resulting light penetration depth (G) is calculated as
sPc
 saa PPP c31 . b) Absorption
spectra of the photosensitizers porfimer sodium and m-tetrahydroxyphenylchlorin
(Triesscheijn et al. 2006a).
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1.3.1 Light sources 
Vast amounts of light are required during PDT. Tissues are typically exposed to 
irradiances around 100 mW cmÞ2, which is comparable to the maximum total solar 
irradiance in southern Norway (Huld & Suri 2006). The treatment modality has to 
some extent been limited by the availability of adequate light sources providing 
sufficient output powers of red light. However, reliable semiconductor-based light 
sources have become available during the last 5–10 years. Such diode lasers and light 
emitting diodes (LEDs) are currently the dominating light sources in PDT. 
Laser light with a wavelength matching the absorption maximum of the photo-
sensitizer provide the most efficient excitation. When using a laser it is also possible 
to couple the light into an optical fiber to illuminate sites such as the esophagus, 
prostate, oral cavity or brain (Figure 7c). In cases where the use of fiber optics is not 
necessary, sufficient excitation may in many cases be achieved using broadband light 
sources such as LEDs or filtered incandescent lamps (Figure 7 a and b) (Brancaleon 
& Moseley 2002). Systems based on arrays of high power LEDs are currently domi-
nating for PDT in dermatology in Europe. Compared to diode lasers, LED systems 
are cheaper, more compact, and do not represent any risk for retinal injury (ICNIRP 
1997).
1.3.2 Light dosimetry 
The simplest way to describe the light dosimetry of a PDT session is to specify the 
amount of light delivered to the tissue. When treating a surface, the dose is then 
specified as the time integral of the irradiance. The irradiance, E, has unit W cmÞ2
and is defined as the radiant power entering a surface, divided by the surface area. 
When treating with an indwelling applicator, like a fiber tip embedded in the tissue, 
the dose can be specified as the total radiant energy delivered from the applicator. 
More sophisticated light dosimetry involves calculating the actual fluence rate distri-
a   b   c 
Brain
Skull
Skin
Fiber coupled
to laser source
Figure 7: Light sources developed for PDT: (a) a filtered halogen lamp and (b) an LED lamp for light 
delivery to skin. c) Indwelling balloon applicator for light delivery to the brain (Madsen et al. 2001). 
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bution inside the tissue. The fluence rate, I, has unit W cmÞ2 and is defined as the 
radiant power passing through an infinitesimal sphere divided by the sphere’s cross-
sectional area. The fluence rate distribution for a specific treatment session depends 
on both the geometry and the optical properties of the tissues. It can be calculated by 
solving the Boltzmann transport equation, a partial differential equation describing
the transport of light in turbid media, or by using Monte Carlo simulation to sto-
chastically imitate the propagation of photons through turbid media (Star 1997). 
Figure 8 shows examples of calculated fluence rate distributions for two light deliv-
ery geometries. 
The ultimate dose measure in PDT is the distribution of the 1O2 formation, 
which depends on the treatment variables light, photosensitizer, and oxygen. How-
ever, the distribution of 1O2 is very difficult to calculate since these three factors are 
far from constant during the light exposure (Wilson et al. 1997): The PDT effects
alter the blood supply and hence the oxygen supply. The oxygen concentration is 
also reduced as oxygen is consumed by the production of 1O2. In addition, the 
photosensitizer concentration is in most cases significantly reduced (photobleached)
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Figure 8: Light distributions calculated for (a) external and (b) interstitial light delivery.
Calculations were made for a surface exposed to a 2 cm beam with irradiance 100 mW
cmÞ2, and an infinite medium with an isotropic point source of 100 mW. The fluence
rates are visualized as iso–fluence rate contours (unit: mW cmÞ2) and as a function of 
depth. For the external delivery the fluence rates were calculated using the Monte Carlo
software MCML (Wang et al. 1995). For the interstitial delivery the expression
   rP
r
as
GPPS

c e43 , which is derived using the diffusion approximation of the Boltz-
mann transport equation, was used (Driver et al. 1991). In both cases the optical proper-
ties of the medium were set to Pa = 0.5 cmÞ1, = 10 cmsPc
Þ1 and G = 0.252 cm. 
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by the presence of light. The change of blood supply, the oxygen consumption, and 
the photobleaching may depend heavily on the rate of the light delivery. To top off 
the complexity, the optical properties of the tissue depend strongly on blood content, 
blood oxygenation, and photosensitizer concentration. Due to these difficulties the
by far most common dose measure in PDT is a simple specification of the light
delivered to the tissue. Calculations of fluence rate distributions are mostly used for 
general purposes, and are rarely performed for a single patient. Recently it has
become possible to assess the 1O2 formation directly by in vivo measurement of 1O2
phosphorescence (Niedre et al. 2002). Massive technical difficulties must be over-
come to introduce such measurements clinically, but they may become a golden 
standard for PDT dosimetry in the future.
1.4 PDT in dermatology
Topical porphyrin precursor mediated PDT is becoming a widespread treatment
modality in dermatology, and the prime indications are currently the non-melanotic
skin cancer basal cell carcinoma (BCC) and the precancerous skin growth actinic
keratosis (AK). BCC (Figure 9) is the by far most common malignancy within the
Caucasian populations, with incidence rates of 100–700 per 100 000 per year de-
pending on solar exposure (Brooke 2005). However, it metastasizes in less than 
0.03% of cases (Lo et al. 1991, Wadhera et al. 2006) and is rarely dangerous. AK 
has an even higher incidence, and has the potential to progress to squamous cell 
carcinoma if untreated (Ortonne 2002). Several efficient treatment options exist for
both BCC and AK, but PDT has the advantage of less treatment related morbidity 
and a better cosmetic result. PDT is particularly advantageous for treatment of large
areas of sun-damaged skin with multiple tumors and premalignancies (Braathen et 
al. 2007). Porphyrin precursor mediated PDT is efficient for AK (Szeimies et al.
2002, Jeffes 2002) and superficial BCC (Kennedy et al. 1990). Good results are also
achieved for thicker subtypes of BCC, like nodular BCC, if most of the tumor mass is 
removed by a debulking procedure prior to the drug application (Soler et al. 1999,
Soler et al. 2001).
Two different drugs are commonly used: ALA and its methyl ester methyl ami-
a   b 
Figure 9: a) Photo and H&E stained histological section of superficial BCC. 
b) Nodular BCC before and after MAL PDT.
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nolevulinate (MAL). An ALA cream formulation (Levulan Kerastick®, DUSA Phar-
maceuticals, USA) is approved in the USA for treatment of AK and is also used 
cosmetically for skin rejuvenation. Topical ALA PDT has also been shown to be 
efficient for treatment of superficial BCC and squamous cell carcinoma in situ 
(Braathen et al. 2007). An MAL cream formulation (Metvix cream®, PhotoCure
ASA, Norway) is approved for treatment of AK (Europe, Australia, USA, Brazil),
squamous cell carcinoma in situ (Europe), and basal cell carcinoma (Europe, Austra-
lia, Brazil). Both MAL and ALA PDT have also recently been proven to have effect
on inflammatory acne (Wiegell & Wulf 2006a, 2006b). Comparative clinical studies 
have shown that MAL leads to more selective porphyrin accumulation (Fritsch et al.
1998, Thompson et al. 2001) and less pain (Wiegell et al. 2003, Kasche et al. 2006)
than ALA. 
Other photosensitizers used successfully to treat non melanotic skin cancer in-
clude porfimer sodium (Photofrin®), verteporfin (Visudyne®), and m-tetrahydroxy-
phenylchlorin (Foscan®) (Lui et al. 2004, Oseroff et al. 2006, Triesscheijn et al.
2006b). These systemically applied drugs can be more powerful than porphyrin 
precursors, but they are also less selective and cause more side effects and less favor-
able cosmetic outcomes. Still, they may be beneficial for treatment of large, tick 
tumors for which porphyrin precursor mediated PDT has a low efficacy.
1.5 PDT of malignant brain tumors 
Malignant brain tumors cause 3% of all cancer deaths in Norway (Kreftregisteret
2006). The main treatment modality is surgery, but even if complete resection is
achieved patients typically relapse, and cure is rare for most subtypes (CBTRUS 
2005). Glioblastoma multiforme (Figure 10), the most common and aggressive 
subtype, has a median survival of 14 months after a combination of surgery, postop-
erative radiation therapy, and chemotherapy (Stupp et al. 2005). Recurrences often
occur from tumor cells invading the normal brain. Although invading tumor cells
can be found far from the tumor border, the recurrent tumors are within 2 cm from 
the resection margin in a majority of the cases (Wallner et al. 1989). It is likely that a 
treatment that eliminates tumor cells embedded in the so-called brain adjacent-to-
tumor (BAT) region would have the potential to reduce the recurrence rate. PDT is
currently being tested clinically for destruction of tumor cells in residual bulk tumor 
and in the BAT after standard surgery, and for ablation of non-resectable tumors in 
selected patients. Several available photosensitizers feature excellent tumor–to–
normal brain selectivity, but animal studies have shown that damage to normal brain 
still occurs if the exposure exceeds a certain light fluence (Lilge & Wilson 1998). 
Furthermore, the selectivity in the BAT can be disrupted by defects in the blood–
brain barrier due to transport of the photosensitizer via edema bulk flow (Stummer
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et al. 1993). It also remains unclear if tumor cells embedded in the BAT are photo-
sensitized.
PDT is not an established treatment modality for brain tumors. Definite patient
benefit has not been confirmed, and the average survival gains reported in pilot
studies are only a few months at best. Most clinical trials have been performed with 
the photosensitizer porfimer sodium and with light delivery to the resection cavity
during open surgery. The first placebo controlled phase III study was recently fin-
ished in Canada and USA (Muller et al. 2006). It showed that this treatment does
not increase patient survival, at least not with the light doses that were considered 
safe for porfimer sodium mediated PDT. Hence, other approaches seem necessary to 
make PDT beneficial for brain tumor patients. 
Sensitizers that are more powerful than porfimer sodium and that absorb at
longer wavelengths, where light penetrates deeper, have been tested both in animal
models and in pilot clinical trials (Lobel et al. 2001, Kostron et al. 2006). There is
also interest in using porphyrin precursor mediated PDT with systemic administra-
tion of ALA. Preclinical data from animal models indicate that compared to other 
sensitizers, ALA photosensitization can lead to a much higher light fluence threshold
for necrosis in normal brain tissue (Lilge et al. 1996, Olzowy et al. 2002). ALA has 
been tested extensively in Germany for fluorescence-guided resection of brain tu-
mors, and recently a pilot study of ALA mediated PDT has shown that the treatment
is safe even for relatively high light doses (Beyer et al. 2006). It was also demon-
strated that ALA PDT with interstitial light delivery can be used to ablate bulk 
tumor tissue in inoperable gliomas. However, taking into account the poor results of 
porfimer sodium PDT it seems unlikely that substantial survival gain can be achieved 
Figure 10: MRI images of a glioblastoma in the
right frontal lobe before and after surgery.
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from a single treatment session. Madsen et al. (2001) have developed an indwelling
light applicator (Figure 7c, page 7) designed to be left permanently in the resection 
cavity after surgery. The intention is then to prevent tumor regrowth by performing 
repeated PDT sessions throughout the rest of the patient’s life. A related approach 
that is being tested in animal models is to assess other mechanisms of cell death and 
selectivity by illuminating over several days with ultra-low light dose rates (Bisland et 
al. 2004).
2 Aims of the study 
This study investigates the porphyrin precursor mediated photosensitization and the 
light delivery for PDT of two different indications: non-melanotic skin cancer and 
malignant brain tumors. The skin studies were a part of developing topical PDT as a
standard treatment modality, and were designed to gather detailed knowledge of the 
accumulation and degradation of porphyrins throughout the drug application and 
light delivery. For the brain studies, an experimental rat model was used to investi-
gate parameters that are relevant for clinical PDT of brain tumors. 
The specific aims of the investigation were: 
x To compare the effects of two different light sources on the porphyrins accu-
mulated in skin tumors during topical application of ALA (publication I). 
x To describe the distribution of porphyrins in skin lesions and normal skin in-
duced by topical application of MAL-creams (publications II and III). 
x To investigate the degree of skin photosensitivity following topical applica-
tion of MAL (publication III). 
x To map the light and temperature distributions during interstitial light deliv-
ery to an experimental rat glioma model, and to estimate the optical and 
thermal properties of brain tissue (publication IV). 
x To evaluate to which degree ALA is able to photosensitize glioma tissue and 
normal brain in a rat model (publications V and VI). 
x To evaluate the effect of the rate of light delivery during PDT in a rat glioma
model (publication V). 
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3 Overview of experimental methods 
An overview of the methods used in this work is presented below. Further details are 
available in publications I–VI. 
Patients and healthy volunteers (publications I–III) 
Patients suffering from AK or BCC were recruited at the outpatient photodynamic
clinic at The Norwegian Radium Hospital (I and II). The healthy volunteers (III)
were students recruited at the Faculty of Medicine at the University of Oslo. 
Animal model (publications IV–VI) 
The applied brain tumor model utilized the gliosarcoma cell line BT4C, which has 
been established by ethylnitrosourea exposure of transplacental rats of the BDIX 
inbred strain (Lærum et al. 1977). The method for intracranial inoculation of the
tumor cells in BDIX rats was refined at Center for Comparative Medicine at Rik-
shospitalet (Sørensen et al. 2002). The in vivo experiments were performed at that
facility, except from the survival experiments involving tumor-bearing rats in publi-
cation VI which were performed at The University of Nevada. Cell cultures of the 
BT4C cell line was also used for in vitro survival experiments (V and VI).
Drugs and formulations (publications I–III, V, VI) 
Skin lesions and normal skin was photosensitized with porphyrin precursors in 
topical oil-in-water formulations. Two distinct creams were used: an ALA formula-
tion with dimethyl sulfoxide added as a penetration enhancer (I) and the MAL 
formulation that has become commercially available under the trade name Metvix®
(II and III). The creams were covered by an occlusive dressing applied for 3–18 
hours. BDIX rats were photosensitized by intraperitoneal (i.p.) injection of a freshly 
prepared solution of ALA in distilled water (V and VI), or by direct intracranial 
injection of a buffered ALA solution (VI). In the in vitro experiments the BT4C cells 
were incubated in 1 or 6 mM ALA in serum-free medium (VI) or 8 mM ALA in 
medium with 10% calf serum (V). Light exposure and/or pharmacokinetic studies
were carried out 1–48 hours following the drug application in the skin studies (I–III),
and 4–5 hours following the drug application in the glioma studies (IV–VI). 
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In situ fluorescence measurements (publications I–III) 
Non-invasive point measurements of surface fluorescence were used to monitor the 
accumulation of photosensitizer in skin and skin lesions. A Perkin Elmer LS-5 spec-
trofluorimeter was used to deliver excitation light at 405 nm and measure fluores-
cence at 635 nm via fiberoptic probes. The probe used in the last study (III) resulted 
in a higher sensitivity for fluorescence detection than the probe used in the two 
former studies (I and II). Both probes had separate fiber bundles for excitation and 
fluorescence light directed towards a single sample area. The last study (III) also 
included measurements using a system based on a CCD spectrometer, which could 
instantly measure the entire fluorescence spectrum. This allowed for a more accurate 
background subtraction, resulting in further improvement of the sensitivity for 
porphyrin fluorescence detection. 
Microfluorometry (publications II, V, VI) 
The photosensitizer biodistribution in thick nodular BCCs (II) as well as rat brain (V 
and VI) was studied by fluorescence microscopy of frozen sections. Tissues were cut 
to 8–10 Pm thick sections that were studied under blue excitation light. The sections 
were then H&E stained for histological identification of tissue types. Image analysis 
was used to quantify the average fluorescence intensity within a region of interest as 
a function of the distance to an arbitrary line. This analysis was used to derive depth 
profiles of the porphyrin distribution in nodular BCCs (II), and to estimate the 
porphyrin content in glioma and brain tissue as a function of distance to the tumor 
border (V).
Light exposure (publications I, III–VI) 
Skin and skin lesions were irradiated using a light source with a filtered halogen 
lamp. The system used to irradiate superficial BCCs (in publication I) was a proto-
type of the CureLight BroadBand® light source used in publication III. The two 
systems delivered equivalent irradiances of visible light exciting the photosensitizer, 
but the prototype had more residual output of thermal infrared light. Rat brains and 
BT4C glioma cells (IV–VI) were irradiated using lasers with wavelengths within the 
635 nm peak of the PpIX excitation spectrum. Most of the animals were irradiated 
using a diode laser with wavelength 632 nm, where PpIX is excited with at least 
90% of the yield at the optimal 635 nm. The light was delivered interstitially from 
bare 400 Pm fiber tips positioned stereotactically. The output power was in the 
range 4.8–45 mW in the PDT experiments (V and VI) and 15 or 100 mW during 
measurements of intracranial fluence rates or temperatures (IV). 
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Measurement and modeling of interstitial light delivery (publications IV, V) 
Interstitial probes were assembled and used for stereotactic mapping of intracranial 
fluence rate and temperature. Publication IV describes how models based either on 
the diffusion approximation of the transport equation or on Monte Carlo simulation 
of light propagation were fitted to the measured data. The Monte Carlo model was 
then used in publication V to estimate the fluence rates and fluences achieved in 
tumor and brain tissue during interstitial PDT. 
Evaluation of treatment effects (publications I, III, V, VI) 
The PDT effect in normal skin (III) was evaluated by scoring erythema and pain and 
by evaluating adverse events such as edema and hyperpigmentation. Also, photo-
bleaching of the photosensitizer during light exposure was measured in superficial 
BCCs (I) and normal skin (III). The PDT effects on rat glioma and normal brain was 
evaluated by recording symptom free survival, by observing the morbidity and 
mortality after light exposure, and by histopathology 15–72 hours post treatment. 
The histopathology included scoring of tumor necrosis and invasion of neutrophils 
from H&E stained sections (V and VI), as well as evaluation of edema from sections 
that were immunostained for plasma protein (V).

4 Synopsis of the results 
Publication I:
The bulk of this publication is a clinical trial comparing ALA PDT of superficial 
BCCs using either 570–740 nm broadband or 630 nm laser light. The trial involved 
245 lesions in 83 patients and concluded that 100 J cm–2 of laser light and 200 J cm–2
of broadband light resulted in the same response rates, cosmetic outcomes, and 
adverse events. The publication also includes a technical comparison of the two light
sources in terms of spectral output and ability to photobleach PpIX. The spectral 
irradiance of the broadband light source was measured, and calculations of the 
product integral with the PpIX excitation spectrum suggested that it excited PpIX at
43% of the rate of the laser. Porphyrin fluorescence was measured during light 
exposure of BCCs. The measurements indicated that the light doses used during the 
clinical trial were able to photobleach at least 98% of the photosensitizer present in 
the tumor tissue. There was a tendency to more efficient photobleaching for laser 
light compared to broad band light, but the data was not sufficient for accurate
comparison of the bleaching rates. 
Publication II:
The publication presents pharmacokinetic studies investigating the porphyrin induc-
ing effect of MAL creams applied to normal skin, AK, superficial BCC, and thick 
nodular BCC, varying the cream application time and the MAL concentration.
In vivo surface fluorescence measurements were used to monitor porphyrin ac-
cumulation in 18 superficial BCCs, 32 AKs, and adjacent normal skin sites. For both
lesion types, the fluorescence increased during the first 13 of 28 hours of continuous
MAL application. In normal skin the lowest cream concentration (16 mg g–1) re-
sulted in less fluorescence than the higher concentrations (80 and 160 mg g–1). There 
were no corresponding statistically significant dependencies in AK or BCC. How-
ever, the statistical power to detect MAL concentration dependencies was poor, due
to 20-fold lesion-to-lesion variation in the fluorescence intensity. The selectivity
between lesions and normal skin was tenfold during the first hours and decreased 
throughout the application time.
Fluorescence in 32 thick nodular BCCs was studied by analyzing images of fro-
zen tissue sections from biopsies sampled after 3 or 18 hours of MAL application.
Fluorescence microscopy images were used to calculate the porphyrin content in 
19
SYNOPSIS OF THE RESULTS20
tumor tissue as a function of depth. Within the tumors treated for 3 hours, the 
average fluorescence intensity depended on the MAL concentration. Increase to 18-
hour MAL application significantly enhanced the fluorescence levels in the superfi-
cial tumor layers, but not in the deep layers. The fluorescence in epidermis covering 
the tumor was comparable to that in tumor tissue after 3-hour application, but 
substantially higher after 18-hour application. 
Publication III:
The publication reports a clinical trial evaluating the duration of porphyrin fluores-
cence and skin photosensitivity after MAL application. Placebo and 160 mg gÞ1
MAL creams were randomly assigned to contralateral sites located at forearms and 
finger tips of 16 healthy volunteers and applied for 3 hours. Surface fluorescence 
measurements showed that the porphyrin fluorescence in forearm skin peaked about 
1 hour after the cream removal, was halved after 8 hours, and was reduced by more 
than 90% within 24 hours. Exposure to 50 J cm–2 of broadband light 1 and 8 hours 
following cream removal induced phototoxic reaction in most MAL treated sites. Six 
subjects also got reactions from exposure at 24 hours following cream removal. At 
this time, the phototoxicity was positively correlated with residual porphyrin fluo-
rescence. Following cream removal at 48 hours, no photosensitivity or porphyrin 
fluorescence was detected in any of the subjects. In general, all reactions were mild 
or moderate, and included pain, erythema, edema, and cases of transient hyperpig-
mentation. Sites at fingertips showed a 15 times weaker and much slower develop-
ment of porphyrin fluorescence than the forearm skin, and phototoxic reactions were 
absent except from sporadic cases of mild pain. 
Publication IV:
This publication reports the light and heat distributions during interstitial light 
delivery to the BDIX/BT4C rat glioma model used for photodynamic therapy in 
publications V and VI. Intracranial fluence rates and temperatures were measured 
with interstitial probes. Mathematical models were then used to derive tissue optical 
properties and to predict distributions for general tumor and light application ge-
ometries. The fluence rates in tumor-free brains agreed well with models based on 
diffusion theory and Monte Carlo simulation. In both cases the best fit was found 
for absorption and reduced scattering coefficients of 0.57 and 28 cmÞ1, respectively. 
In brains with implanted BT4C tumors, a discrepancy between the diffusion and 
Monte Carlo–derived two-layer models was found. The estimates of optical proper-
ties for tumor tissue differed, but both models predicted higher absorption and less 
scattering than in normal brain. Temperatures were measured by inserting thermo-
couples directly into tumor-free brains. A model based on diffusion theory and the 
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bioheat equation was found to be in good agreement with the experimental data and 
predicted a thermal penetration depth of 0.60 cm in normal rat brain. 
Publication V:
The publication reports the effect of PDT using systemic ALA and interstitial light 
delivery to the BDIX/BT4C glioma model, focusing on the effect of low light delivery 
rates. In vitro experiments showed that the sensitivity of BT4C multicellular tumor 
spheroids to ALA-PDT depended on the rate of light delivery (fluence rate). BT4C
tumors were established intracranially in BDIX rats. Microfluorometry of frozen 
tissue sections showed that photosensitizer was produced with hundredfold tumor-
to-normal tissue selectivity after ALA injection, and suggested that 60, 125 and 250 
mg kgÞ1 of ALA i.p. resulted in similar porphyrin levels. Four hours after ALA 
injection (125 mg kgÞ1 i.p.), tumor-bearing animals were treated with 26 J of 632 nm 
light delivered interstitially over 15 (high fluence rate group) or 90 (low fluence rate 
group) minutes. Two groups of 7 animals were treated 14 days after tumor induction 
and were studied by histopathological examination. There was extensive tumor 
necrosis after low fluence rate PDT, but hardly any necrosis after high fluence rate 
PDT. Neutrophil infiltration in tumor tissue was increased by PDT, but was similar 
for both treatment regimens. A low fluence rate PDT applied 9 days after tumor 
induction resulted in statistically significant prolongation of survival compared to 
non-treated control animals. 
Publication VI:
This publication focuses on the effects of interstitial ALA-PDT on small clusters of 
BT4C tumor cells embedded in the normal brain of BDIX rats. Treatment of tumor-
free animals demonstrated that ALA-PDT can do significant damage to normal brain 
if the light fluence is sufficient. Light doses that were safe in the tumor-free animals 
were used to treat rats 2 days after tumor induction. The treatment failed to prolong 
the survival compared to untreated controls. In contrast, animals inoculated with 
tumor cells pre-incubated in vitro with ALA showed a significant survival advantage 
in response to PDT. Consistent with publication V, it was also found that PDT 
caused significant damage to tumor tissue if the treatment was performed 15 days 
after the induction. However, histopathology showed that there were viable cells in 
the tissue invading the normal brain, in spite of the extensive necrosis in gross tumor. 
Fluorescence microscopy of frozen tissue sections showed that the photosensitizer 
content was limited and inhomogeneous in the invading tumor tissue. The results 
show that ALA-PDT could not prevent tumors from forming if the treatment was 
performed shortly after tumor initiation. This was probably due to insufficient levels 
of ALA and/or PpIX in the glioma cells. 

5 General discussion 
5.1 Porphyrin accumulation in normal and tumor tissues: 
selectivity of the photosensitization
The degree of photosensitization following application of porphyrin precursors
depends on the three following steps: (1) Distribution of the porphyrin precursor 
into the tissue, (2) cellular uptake of the porphyrin precursor and conversion into
photosensitive porphyrins, and (3) relocalization, degradation and clearance of
porphyrins and porphyrin precursors. The selective photosensitization observed for 
the two different biological systems studied in this thesis can be due to discrepancies 
of tumor tissue compared to normal tissue in each of the three steps. The following 
sections discuss the relevance of each factor for the skin and the brain studies. 
For skin tumors, Wennberg et al. (2000) have demonstrated that the transport
of topical ALA into superficial BCC is much more efficient than into normal skin. It
is likely that this is the case also for the porphyrin precursor MAL used in publica-
tion II, and that this preferential distribution was a major factor for the observed 
selectivity of porphyrin fluorescence for BCC and AK (publication II, Figure 2). 
Another factor contributing to the selectivity is the conversion of MAL into por-
phyrins. Porphyrins are produced in neoplastic cells and in the epithelial cells of the 
epidermis, but very little is produced in the dermis (Kennedy et al. 1990, Peng et al.
2001). The dermis consists mostly of connective tissue rather than cells converting 
MAL into porphyrins. The porphyrin fluorescence observed from the surface of 
normal skin (publications II, Figure 2; and III, Figure 1) is from the epidermis, which
is thinner—and consequently emit less fluorescence—than the neoplastic tissue in the
AKs and BCCs. In addition to this geometrical factor, lesions can have increased
fluorescence due to altered activity of the hem synthesis in neoplastic cells (Figure 4, 
page 4). This effect is seen in several in vitro studies reporting higher porphyrin 
accumulation in tumor cell lines than in normal cell lines. However, the rate of the 
hem synthesis is known to differ for different tumor types (Collaud et al. 2004), and 
it is not known whether the neoplastic cells in AK and BCC have increased PpIX
production compared to the normal epithelial cells in the epidermis. According to the 
results from nodular BCCs, there seemed to be little selectivity related to increased 
conversion in the tumor cells. The fluorescence images analyzed in publication II 
indicate that the epidermis had a porphyrin concentration comparable to that in the 
underlying tumor (publication II, Figure 4a). Actually, after 18 hours of MAL cream 
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application (publication II, Figure 4b) there was significantly more porphyrin fluo-
rescence in the epidermis than in the underlying tumor. 
The shape of the profiles at 18 hours compared to at 3 hours, with the fluores-
cence decreasing with increasing depth, suggests that the penetration of MAL into 
the tumors was limited by clearance to the tumor vasculature. Such clearance will 
not take place in the epidermis since it is not vascularized. Thus, the observed limita-
tion in selectivity for nodular BCCs was probably due to clearance of MAL. Limited 
selectivity for long application times was the case also for superficial lesions (publica-
tion II, Figure 3), but this effect might as well be caused by saturation (publication II, 
Figure 2) of the porphyrin synthesis in the AK and BCC cells combined with slow 
penetration of MAL into normal epidermis. 
For the brain tumor model, the biodistribution studies demonstrated tenfold se-
lectivity versus the BAT (publication V, Figure 4) and hundredfold selectivity versus 
normal gray matter far from the tumor (publication V, Table 2). It is clear from the 
literature that for brain tumors the distribution of the porphyrin precursor contrib-
utes to selectivity. In general, there is low transfer of ALA into normal brain through 
the blood–brain barrier. The influx rate has been quantified by Ennis et al. (2003). 
Their results agree with the plasma and brain levels in pharmacokinetic studies 
employing 14C-labelled ALA and doses relevant for PDT (Hua et al. 1995, Obwege-
ser et al. 1998). However, Obwegeser et al. found that the ALA concentration ratio 
between implanted C6 brain tumors and normal brain was merely 4:1. (In the same 
study the corresponding ratio for the sensitizer m-tetrahydroxyphenylchlorin (Figure
1, page 1) was 80:1.) This suggests that selectivities better than 4:1 are caused by a 
low conversion into photosensitive porphyrins for the ALA distributed to the normal 
brain.
As reported in publication V, there was no detectable porphyrin fluorescence in 
normal gray matter far from the tumor (publication V, Table 2). The same result was 
found by Hebeda et al. (1998) in an extensive biodistribution study involving two rat 
tumor models. Conversely, Stummer et al. (1998) and Lilge et al. (1998) reported 
significant porphyrin levels in normal brain, causing only tenfold tumor selectivity in 
rat and rabbit models, respectively. The discrepancy in the observed porphyrin levels 
in normal brain can be due to differences between the implanted tumors. Hebeda et
al. (1998) and Stummer et al. (1998) both showed that the porphyrin content in the 
normal brain was related to edematous flow from the tumor. Such indirect photo-
sensitization was observed also in the present work, as a resemblance between the 
porphyrin fluorescence patterns and the edema immunostaining pattern (publication 
V, Figure 7). Hence, the photosensitization of the normal brain is influenced by the 
nature of the implanted tumor, and the observed porphyrin level depends on the 
tumor’s ability to photosensitize the brain indirectly. 
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Nevertheless, the mortality of the tumor-free rats following ALA PDT (publica-
tion VI, Figure 4) clearly showed that ALA has a potential for direct photosensitiza-
tion of normal brain. The histopathology (publication VI, Figure 5) and the response
to steroid treatment (publication VI, Figure 4) demonstrated that both neuron necro-
sis and brain edema could have contributed to the mortality. In agreement with our 
results, ALA PDT effects in tumor-free animals have been reported previously for 
two different species. For rabbit brain, ALA PDT and porfimer sodium PDT with
interstitial light delivery caused similar levels of necrosis in gray matter (Lilge & 
Wilson 1998). For rat brain, the two drugs have been compared for PDT with exter-
nal irradiation of the cortex. In that setup, only porfimer sodium caused noticeable 
necrosis (Olzowy et al. 2002), but significant edema occurred in the cortex after 
ALA PDT (Ito et al. 2005). 
5.2 Light dosimetry
Although skin lesions and brain tumors are entirely different tumor types, it is of
some interest to compare the light dosimetry. The light distribution in the rat model
was described in terms of fluences and fluence rates (publications IV and V)1,
whereas in the skin studies (publications I–III), it was simply specified as the expo-
sure of the tissue surfaces. To compare the light dosimetries, the fluence rates in the 
skin must be estimated. Figure 11 shows the light distributions that can be expected 
during PDT of skin, BCC, and AK. The calculation was based on a multi layer skin
model were the optical properties are estimated from assumed levels of melanin and 
Figure 11: Calculated distributions of 635 nm light
in skin with varying melanin and blood content. The
graphs show fluence rate relatively to the irradiance
as a function of depth, for skin with 1.3% (ŷ) or
6.3% (ŷ) melanin in the epidermis (a range that 
covers light Caucasian skin (Dwyer et al. 2002)), and
0.2% (–) 2% (– –) or 5 % (–··–) blood in the dermis.
The calculations were made with a public domain
Monte Carlo software (Wang et al. 1995). Skin was
modeled as a 60Pm epidermal layer covering a der-
mis with equal amounts of oxygenated and deoxy-
genated hemoglobin. Optical properties for
wavelength 635 nm were derived from spectra pub-
lished online by Jacques et al. (1998).Depth (mm)
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1 The results from publication IV were used in publication V, but with preliminary estimates of
optical properties that resulted in slightly decreased estimates for fluence rates and fluences. However,
the discrepancy was only 10%.
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hemoglobin. The blood volume fraction in normal skin is about 0.2% on the average 
through the dermis, and about 2–5% in the most vascularized layers (Jacques 1996). 
This range is covered by the calculations of Figure 11. BCCs and AKs have been 
reported to have a 5–10-fold increased blood content compared to the average in 
normal skin (i.e. 5–10 ﬂ 0.2%) (Newell et al. 2003), which also is within the range 
used in the calculations.
Spectral characteristics of the light also play a major in the dosimetry. As ex-
plained in publication I (page 725, “Calculation of the relative phototherapeutic
efficiency”), more broadband light than monochromatic light must be applied to 
achieve a certain PDT effect. According to the product integral of the action spec-
trum for ALA PDT and the lamp emission spectrum, the broadband light was 40% 
as efficient as 632 nm monochromatic light. To calculate this factor, PpIX’s fluores-
cence excitation spectrum was (as in publication I) used to approximate the action 
spectrum. The factor is taken into account in Table 1, which estimates the fluences 
and fluence rates inside skin and skin lesions, based on the distributions in Figure 11.
Estimates are made for 50 and 200 J cmÞ2, the exposure used in publications I and
III; 100 J cmÞ2, the exposure that resulted in 99% photobleaching of surface fluores-
cence in publication I; and for 75 J cmÞ2, an exposure proven sufficient for successful 
PDT of AK and BCC in several clinical trials (Foley 2003). 
When comparing the data in Table 1 to the estimates calculated in publication
V, the fluences in skin and skin lesions are comparable to, or lower than, the fluences
delivered to the brain tumors (publication V, Table 1). Accordingly, the fluence rates
are comparable to, or higher than, the fluence rates in the brain tumors of the ‘Low 
fluence rate’ group. Hence, PDT with the light delivery that was sufficient to photo-
Table 1: Minimum fluences and fluence rates in skin and skin lesions for dif-
ferent light exposures and depths.
Site Exposure of surface* Depth Dosimetry inside tissue† 
Dose Irradiance Fluence Fluence rate
(J cmÞ2) (mW cmÞ2) (J cmÞ2) (mW cmÞ2)(mm)
Normal skin   50 150   0.1‡ 50–90 150–270
BCC 100 180 0.1 100–160 180–290
  1.0§BCC 200 180 140–220 130–190
BCC or AK   75 180 0.5   80–110 190–250
BCC or AK   75 180 1.0 60–80 140–190
*Values for the applied broadband light source. 
†Corrected with a factor 0.40 to represent values equivalent to 632 nm laser light.
‡Approximately the thickness of the epidermis. 
§Maximum thickness of lesions in publication I.
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bleach most surface fluorescence in skin (publications I and III), and to successfully 
treat BCCs and AKs, was insufficient to treat the rat brain tumors (publication V). 
The PDT could only increase the survival for tumor-bearing rats by a few days 
(publication V, Figure 8), although the tumors in that experiment were relatively 
small and received fluences of at least 200 J cmÞ2. This indicates that systemic ALA 
application did not photosensitize brain tumors to the same degree that topical ALA 
or MAL is able to photosensitize skin lesions. Publication VI shows that the porphy-
rin accumulation was limited and variable in tumor tissue invading the normal brain. 
This limitation, possibly in combination with insufficient light exposure, may have 
prevented a complete cytoreduction (publication V, Figure 6a). A similar incomplete 
cytoreduction was observed by Olzowy et al. (2002), who found a non-homogenous 
distribution of phototoxic damage after ALA PDT in the C6 rat glioma model. The 
non-homogenous damage suggests that inhomogeneous photosensitizer and/or 
oxygen supply, rather than insufficient fluence, was the major limitation. However, 
this was not verified, as the severe side effects of PDT prevented experiments that 
might have ruled out insufficient fluence as a limiting factor for ALA PDT in the rat 
model.
5.3 Drug and light delivery for PDT of skin lesions 
The approved dose regimen for MAL PDT is application of 160 mg gÞ1 cream for 3 
hours, followed by exposure to 75 J cmÞ2 of broadband light (or the equivalent 37 J 
cmÞ2 of 610–660 nm LED light (Juzeniene et al. 2004)). This recommendation is 
mainly based on evidence from studies of response rates (Foley 2003), but also on 
the results from the clinical trials described in publications I and II. The advantages 
of using the 160 mg gÞ1 MAL cream and a 3-hour drug–light interval are thoroughly 
discussed in publication II. For this drug dosage, the porphyrin fluorescence was 
selective for the tumor tissue and was distributed more than a millimeter into thick 
BCCs. The high response rates found in several studies demonstrate that sufficient 
photosensitization of AK and BCC lesions is achieved (Foley 2003). Furthermore, the 
results in publication III demonstrate that the photosensitization of normal skin is 
too low to cause severe damage. Selectivity does not appear to be a limiting factor 
for MAL PDT in the skin when 160 mg gÞ1 MAL cream is applied for 3 hours.  
In some cases, a BCC or AK lesion does not respond well to MAL PDT. Two 
treatment cycles are often required to achieve good results (Braathen et al. 2007). 
Two-year accumulated treatment failure rates of around 25% have been reported for 
so-called “difficult to treat” nodular BCCs (Horn et al. 2003, Vinciullo et al. 2005), 
and the 3-year recurrence rate for nodular BCCs is around 15% (for thick debulked 
tumors) (Soler et al. 2001). The cases of treatment failure might be due to incomplete 
photosensitization of the neoplastic tissue. The fluorescence depth profiles from 
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nodular BCCs (publication II, Figure 4a) show an intensity decrease below 1.0–1.2 
mm. The intensity also varied considerably from lesion to lesion, and in some cases 
there was considerable local variation across a single lesion (results not shown). The 
tumors in publication II were not debulked. Debulking is necessary to treat thick 
nodular BCCs (Warloe 1995), probably because it improves the penetration of MAL 
into the tumor tissue. This suggests that the observed variation in the fluorescence in 
the thick BCCs was due to insufficient availability of MAL. However, insufficient 
photosensitization can in general also be due to poor porphyrin synthesis in the 
tumor cells. Morgan et al. (2004) have showed that the cellular expression of the 
peripheral benzodiazepine receptor—a crucial component in the heme synthesis 
(Figure 4, page 4)— can be heterogeneous in BCCs, particularly for subtypes that 
respond poorly to PDT. According to their results, some tumors may respond poorly 
PDT, even if there is adequate penetration of both the porphyrin precursor and the 
light.
The doses of red light used to successfully treat BCC have been in the range of 
50–200 J cmÞ2, delivered at irradiances in the range of 100–200 mW cmÞ2 (Szeimies
et al. 2005, Garcia-Zuazaga et al. 2005). Both laser and broadband sources have 
been used. In the clinical trial of publication I, the ALA treated superficial BCCs 
were exposed to 200 J cmÞ2 of broadband light or 100 J cmÞ2 of laser light. Less light 
was used in publication III, where the MAL treated normal skin sites were exposed 
to 50 J cmÞ2 of broadband light. In both cases, the fluorescence measurements and 
the expected depth of the PpIX biodistribution indicated that at least 98% of the 
available photosensitizer was photobleached during the light exposures. This almost 
complete photobleaching of the sensitizer can explain why the different light sources 
had the same therapeutic effect.  
However, there is not a general direct relationship between PDT-effect and 
photobleaching (Robinson et al. 1999). Particularly in the case of hypoxia, it has 
been demonstrated that PpIX is photobleached independently of the PDT (Dysart & 
Patterson 2006). The tissue oxygenation and the PDT effect can be reduced if the 
fluence rate is too high, i.e., if the applied irradiance is too high (Foster et al. 1991). 
In publication I, the irradiance of the laser light was 120–150 mW cmÞ2. Taking into 
account the differences in the emission spectra (publication I, page 725, “Calculation 
of the relative phototherapeutic efficiency”), the effective irradiance of the broad-
band light was 43–77 mW cmÞ2. Hence, in spite of the equal degree of photobleach-
ing, it is possible that more 2 was produced during exposure to broadband light 
than to laser light. Still, no differences between the light sources were seen in the 
clinical trial reported in publication I. This either means that the two light exposure 
alternatives were equivalent with respect to the PDT effect, or that the light exposure 
was not a limiting factor. 
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5.4 Effects, limitations, and clinical relevance of PDT in the 
glioma model
The experiments indicated that ALA PDT may have a potential to treat glioma. 
However, considerable limitations related to light distribution, side effects, and drug 
distribution were also found. The light distribution is discussed in publication IV. 
The penetration depth (G) in normal rat brain was found to be 1.4 mm, the same as 
previously reported for human brain (Muller & Wilson 1986). The tumor had G
around 1.7 mm, which is less than the 2.4–3.8 mm reported for human tumors and 
BAT (Muller & Wilson 1986, Beck et al. 2003). According to the calculations in 
publication IV, the limited light penetration in BT4C tumors was due to strong light 
absorption (Pa,tumor = 1.4 cmÞ1). The high Pa,tumor was not unexpected, as BT4C tumor 
tissue is well vascularized (Sørensen et al. 2002) resulting in enhanced light absorp-
tion by hemoglobin. During PDT, when the tumor contains light absorbent photo-
sensitizer, Pa,tumor is likely to be further increased. 
The high light attenuation and the use of an implanted point source resulted in 
strong spatial gradients in the delivered fluences (publications IV, Figure 4; and V, 
Table 1). In patients, the larger light penetration depth and the use of non–point 
source applicators would result in smaller gradients. Still, the fraction of the brain 
exposed during PDT in rats will generally be much larger than in the human brain. 
Furthermore, the small size and limited buffering volume of the rats’ intracranial 
space quickly leads to increased pressure following PDT, as a result of cerebral 
edema and normal tumor progression. These differences between small animals and 
humans are important for the interpretation of the observed mortality and morbidity 
(publications V and VI). Recently, no severe side effects were observed among 41 
patients participating in a pilot study of ALA PDT for malignant glioma (Beyer et al.
2006). The study included both intraoperative treatments and minimally invasive 
interstitial treatments. In both cases, the BAT was exposed to fluences at least 5 
times higher than for the rats in publication V (W. Beyer, personal communication). 
This strongly suggests that the severity of the side effects observed in the rat model is 
not clinically relevant. 
It was evident that the ALA PDT was not effective if the light was delivered at 
too high fluence rates, and this is discussed in detail in publication V. At lower 
fluence rates the treatment was effective for gross tumor, but (as explained in publi-
cation VI) it failed to treat the invading part of the tumor. Treatment of gross tumor 
can be valuable for inoperable patients. However, in most cases of malignant glioma 
the core is necrotic, and the tumor growth mainly takes place in the border region 
(Preusser et al. 2006). The prime target for the PDT is thus the tumor border region 
and the BAT. As described above, the fluences in the rat model were limited by side 
effects that are not necessarily clinically relevant. It is possible that higher fluences 
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could have inactivated the tumor border more completely. The porphyrin fluores-
cence was inhomogeneous, but even the areas with the lowest fluorescence had 
similar fluorescence as the BAT (publication VI, Figure 3), and this level (publication 
V, Figure 4) may have been sufficient to inactivate tumor cells if the light fluence had 
been sufficient. However, even when the treatment was preformed 2 days after the 
tumor cell inoculation (publication VI, Figure 7), ALA PDT failed to prolong the 
survival. In these cases the cells were positioned 1–2 mm from the fiber tip, and 
should have received high fluences. Hence, the small newly implanted BT4C tumors 
embedded in normal brain were not significantly photosensitized by the ALA distri-
bution. This experiment needs to be repeated with other tumor models to investigate 
to which degree insufficient photosensitization is a general phenomenon for systemic 
ALA distribution to brain tumors. 
6 Conclusions 
x Both 200 J cm–2 of red broadband light and 100 J cm–2 of 630 nm laser light 
was sufficient to photobleach the porphyrins formed in superficial BCC after
topical ALA application to below 2%. This can explain why PDT with the 
two light sources resulted in the same response rates and cosmetic outcomes. 
x The porphyrin fluorescence intensity in the surface of BCCs and AKs in-
creased, and the lesion to normal skin selectivity ratio decreased, during the 
first 13–20 hours of continuous MAL application. However, application for 3 
and 18 hours resulted in similar porphyrin fluorescence levels in the deeper 
layers of thick nodular BCCs. Only for the 3-hour application the fluores-
cence depended significantly on the MAL concentration in the cream.
x Topical MAL application for 3 hours followed by exposure to red light in-
duced mild or moderate phototoxicity in normal skin. The photosensitivity
ceased within 24–48 hours after cream removal, and its duration was associ-
ated with the degradation of porphyrins.
x In the rat glioma model, intracranial fluence rates and temperatures measured
during interstitial light delivery corresponded well to mathematical models of 
light propagation. The models were used to estimate the fluence rate and
temperature distributions occurring during PDT. An absorption coefficient of
0.57 cmÞ1, a reduced scattering coefficient of 28 cmÞ1, and a thermal penetra-
tion depth of 0.60 cm was estimated for the rat brain. 
x Reduction of the light delivery rate strongly enhanced the effect of interstitial
ALA PDT on glioma tissue. 
x ALA PDT caused significant necrosis in gross glioma tissue. However, the cy-
toreduction was not complete, and only minor tumor growth delay was
achieved. The light dose usable in the experiments was limited by severe side 
effects that were probably related to the small size of the rat brain.
x The ALA application induced highly selective porphyrin production in glioma 
tissue, but the porphyrin levels in the region of the tumor invading the normal 
brain were inhomogeneous and limited. Systemic ALA distribution did not
photosensitize microclusters of newly implanted glioma cells.
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7 Future prospects 
7.1 Optimization of MAL PDT for skin lesions 
There are no published clinical studies comparing the efficacy of different light doses
for MAL PDT of skin lesions. For MAL PDT, the multicenter studies leading to 
approval for AK and BCC have all been performed with 75 J cmÞ2 of broadband
light (or 37 J cmÞ2 of 610–660 nm LED light). At the Norwegian Radium Hospital, 
successful MAL PDT of superficial BCC has been achieved using just 50 J cmÞ2 of
broadband light (Warloe et al., personal communication1). A clinical trial comparing
different light doses could establish the minimum light dose necessary for MAL PDT
for different lesion types. The primary end point in such a study would be treatment 
response rates, but analysis of light penetration and photobleaching would be of 
interest when interpreting the data.
At present, an LED light source (Aktilite®, PhotoCure ASA, Norway) with an ir-
radiance of 75–90 mW cmÞ2 is by far the most common light source for MAL PDT.
Light sources with higher irradiances could be assembled using LEDs with a higher
output power. Up to 200 mW cmÞ2 can be applied to skin without causing hyper-
thermia. At this irradiance the 37 J cmÞ2 can be delivered in just three minutes. 
However, it would be necessary to perform a clinical trial investigating if the in-
creased irradiance affects the treatment response and the pain felt during the light 
exposure.
In some cases, a thick BCC is too dense to allow the debulking that is consid-
ered essential for successful MAL PDT. At The Norwegian Radium Hospital such
lesions are prepared by making perforations through the surface with a cannula or
needle. This is thought to enhance the penetration of MAL, but the effect of the 
procedure has not been documented. A biodistribution study, using the same meth-
ods as in publication II, would demonstrate whether the perforation procedure does 
enhance the porphyrin accumulation in the tumor tissue. 
1 Complete response of 90%, sustained for at least 5 years in 359 of 397 superficial BCCs after a
single MAL PDT. 
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7.2 PDT of brain tumors 
Further experiments using the BT4C rat glioma model that would be of interest 
include: To quantitatively measure the amount of PpIX formed in normal brain 
using chemical extraction of porphyrins; to investigate whether the increased survival 
observed for low fluence rate PDT (publication V, Figure 8) can be enhanced by 
increasing the light dose; to increase the steroid dose in attempt to reduce side effects 
related to brain edema; and to find out if ALA PDT kills glioma cells by apoptosis, 
and whether this depends on the fluence rate. The observation that newly implanted 
BT4C cells are not photosensitized by systemic ALA distribution may indicate a 
critical limitation of ALA PDT, and should be tested using other animal glioma 
models.
If complete cytoreduction can not be achieved by a single ALA PDT session, the 
treatment modality may still be effective by using multiple treatments. This strategy 
has proven useful for topical MAL PDT of skin cancer, where tumors responding 
poorly to a single treatment often are cured by multiple treatments (Braathen et al.
2007). Pilot experiments with the BT4C model indicated that the observed side 
effects of ALA PDT can be a major obstacle for testing repetitive PDT in rats (un-
published results). Furthermore, the model features a life span from inoculation to 
lethal tumor of only 20 days. A more realistic, slow growing tumor model would be 
more suitable to test clinically relevant repetitive PDT schedules. Alternatively, 
repetitive ALA PDT could be tested directly in patients. If (single treatment) intrac-
ranial ALA PDT is proven safe by the ongoing clinical trial in Munich (Beyer et al.
2006), one way to enhance the treatment would be to perform repeated treatments. 
References
Ackroyd R., Kelty C., Brown N., and Reed M. (2001): The history of photodetection 
and photodynamic therapy. Photochem.Photobiol. 74: 656–669. 
Beck T.J., Beyer W., Pongratz T., Stummer W., Waidelich R.M., Stepp H., Wagner
S., and Baumgartner R. (2003): Clinical determination of tissue optical properties
in vivo by spatially resolved reflectance measurements. Proceedings of SPIE 5138:
96–105.
Berg K., Selbo P.K., Weyergang A., Dietze A., Prasmickaite L., Bonsted A., 
Engesæter B.O., Angell-Petersen E., Warloe T., Frandsen N., and Høgset A. 
(2005): Porphyrin-related photosensitizers for cancer imaging and therapeutic ap-
plications. J.Microsc. 218: 133–147. 
Beyer W., Beck T.J., Stepp H., Tonn J.C., Reulen H.J., Kreth F., and Stummer W. 
(2006): Munich experiences with 5-ALA-PDT of malignant gliomas. 6th Interna-
tional Symposium on Photodynamic Diagnosis and Therapy in Clinical Practice, 
October 10–14, (Abstract).
Bigelow C.E., Mitra S., Knuechel R., and Foster T.H. (2001): ALA- and ALA-
hexylester-induced protoporphyrin IX fluorescence and distribution in multicell 
tumour spheroids. Br.J.Cancer 85: 727–734. 
Bisland S.K., Lilge L., Lin A., Rusnov R., and Wilson B.C. (2004): Metronomic 
photodynamic therapy as a new paradigm for photodynamic therapy: rationale 
and preclinical evaluation of technical feasibility for treating malignant brain tu-
mors. Photochem.Photobiol. 80: 22–30. 
Blum H.F. (1941): Photodynamic action and diseases caused by light. Reinhold
Publishing Corporation, New York. 
Braathen L.R., Szeimies R.M., Basset-Seguin N., Bissonnette R., Foley P., Pariser D., 
Roelandts R., Wennberg A.M., and Morton C.A. (2007): Guidelines on the use of
photodynamic therapy for nonmelanoma skin cancer: an international consensus.
J.Am.Acad.Dermatol. 56: 125–143. 
Brancaleon L. and Moseley H. (2002): Laser and non-laser light sources for photo-
dynamic therapy. Lasers Med.Sci. 17: 173–186. 
Brooke R.C. (2005): Basal cell carcinoma. Clin.Med. 5: 551–554. 
35
REFERENCES36
Casas A., Perotti C., Fukuda H., Rogers L., Butler A.R., and Batlle A. (2001): ALA 
and ALA hexyl ester-induced porphyrin synthesis in chemically induced skin tu-
mours: the role of different vehicles on improving photosensitization. Br.J.Cancer
85: 1794–1800. 
CBTRUS (2005): Statistical Report: Primary Brain Tumors in the United States, 
1998–2002. Central Brain Tumor Registry of the United States, USA. 
Chen B., Pogue B.W., Hoopes P.J., and Hasan T. (2006): Vascular and cellular 
targeting for photodynamic therapy. Crit Rev.Eukaryot.Gene Expr. 16: 279–305. 
Cheong W.F. (1995): Summary of optical properties. In: Optical-Thermal Response 
of Laser-Irradiated Tissue, edited by A.J.Welch and M.J.van Gemert, pp. 275–
303. Plenum Press, New York. 
Chopp M., Madigan L., Dereski M., Jiang F., and Li Y. (1996): Photodynamic 
therapy of human glioma (U87) in the nude rat. Photochem.Photobiol. 64: 707–
711.
Collaud S., Juzeniene A., Moan J., and Lange N. (2004): On the selectivity of 5-
aminolevulinic acid–induced protoporphyrin IX formation. Curr.Med.Chem.Anti.-
Canc.Agents 4: 301–316. 
de Rosa F.S. and Bentley M.V. (2000): Photodynamic therapy of skin cancers: 
sensitizers, clinical studies and future directives. Pharm.Res. 17: 1447–1455. 
Dougherty T.J., Gomer C.J., Henderson B.W., Jori G., Kessel D., Korbelik M., 
Moan J., and Peng Q. (1998): Photodynamic therapy. J.Natl.Cancer Inst. 90: 889–
905.
Driver I., Lowdell C.P., and Ash D.V. (1991): In vivo measurement of the optical 
interaction coefficients of human tumours at 630 nm. Phys.Med Biol. 36: 805–
813.
Dwyer T., Blizzard L., Ashbolt R., Plumb J., Berwick M., and Stankovich J.M. 
(2002): Cutaneous melanin density of Caucasians measured by spectrophotometry 
and risk of malignant melanoma, basal cell carcinoma, and squamous cell carci-
noma of the skin. Am.J.Epidemiol. 155: 614–621. 
Dysart J.S. and Patterson M.S. (2006): Photobleaching kinetics, photoproduct for-
mation, and dose estimation during ALA induced PpIX PDT of MLL cells under 
well oxygenated and hypoxic conditions. Photochem.Photobiol.Sci. 5: 73–81. 
Einstein A. (1912): Thermodynamische Begründung des photochemischen Äquiva-
lentgesetzes. Annalen der Physik 37: 832–838. 
REFERENCES 37
Ennis S.R., Novotny A., Xiang J., Shakui P., Masada T., Stummer W., Smith D.E., 
and Keep R.F. (2003): Transport of 5-aminolevulinic acid between blood and 
brain. Brain Res. 959: 226–234. 
Foley P. (2003): Clinical efficacy of methyl aminolevulinate (Metvix) photodynamic 
therapy. J.Dermatolog.Treat. 14 Suppl 3: 15–22. 
Foster T.H., Murant R.S., Bryant R.G., Knox R.S., Gibson S.L., and Hilf R. (1991): 
Oxygen consumption and diffusion effects in photodynamic therapy. Radiat.Res.
126: 296–303. 
Fritsch C., Homey B., Stahl W., Lehmann P., Ruzicka T., and Sies H. (1998): Prefer-
ential relative porphyrin enrichment in solar keratoses upon topical application of 
delta-aminolevulinic acid methylester. Photochem.Photobiol. 68: 218–221. 
Fuchs J. and Thiele J. (1998): The role of oxygen in cutaneous photodynamic ther-
apy. Free Radic.Biol.Med. 24: 835–847. 
Fukuda H., Paredes S., and Batlle A.M. (1992): Tumour-localizing properties of 
porphyrins. In vivo studies using free and liposome encapsulated aminolevulinic 
acid. Comp.Biochem.Physiol.B 102: 433–436. 
Garcia-Zuazaga J., Cooper K.D., and Baron E.D. (2005): Photodynamic therapy in 
dermatology: current concepts in the treatment of skin cancer. Ex-
pert.Rev.Anticancer Ther. 5: 791–800. 
Gaullier J.M., Berg K., Peng Q., Anholt H., Selbo P.K., Ma L.W., and Moan J. 
(1997): Use of 5-aminolevulinic acid esters to improve photodynamic therapy on 
cells in culture. Cancer Res. 57: 1481–1486. 
Gederaas O.A., Holroyd A., Brown S.B., Vernon D., Moan J., and Berg K. (2001): 
5-Aminolaevulinic acid methyl ester transport on amino acid carriers in a human 
colon adenocarcinoma cell line. Photochem.Photobiol. 73: 164–169. 
Hebeda K.M., Saarnak A.E., Olivo M., Sterenborg H.J., and Wolbers J.G. (1998): 5-
Aminolevulinic acid induced endogenous porphyrin fluorescence in 9L and C6 
brain tumours and in the normal rat brain. Acta Neurochir.(Wien) 140: 503–512. 
Hopper C., Kubler A., Lewis H., Tan I.B., and Putnam G. (2004): mTHPC-mediated 
photodynamic therapy for early oral squamous cell carcinoma. Int.J.Cancer 111:
138–146.
Horn M., Wolf P., Wulf H.C., Warloe T., Fritsch C., Rhodes L.E., Kaufmann R., de 
Rie M., Legat F.J., Stender I.M., Soler A.M., Wennberg A.M., Wong G.A., and 
Larkö O. (2003): Topical methyl aminolaevulinate photodynamic therapy in pa-
tients with basal cell carcinoma prone to complications and poor cosmetic out-
come with conventional treatment. Br.J.Dermatol. 149: 1242–1249. 
REFERENCES38
Hua Z., Gibson S.L., Foster T.H., and Hilf R. (1995): Effectiveness of delta-
aminolevulinic acid-induced protoporphyrin as a photosensitizer for photody-
namic therapy in vivo. Cancer Res. 55: 1723–1731. 
Huld T. and Suri M. (2006): PVGIS Solar Irradiance Data Utility.
http://re.jrc.ec.europa.eu/pvgis/sunraddayframe.php, PVGIS: Geographical As-
sessment of Solar Energy Resource and Photovoltaic Technology, European Com-
mission, DG - Joint Research Centre, Institute for Environment and Sustainability, 
Ispra, Italy. 
ICNIRP (1997): Guidelines on limits of exposure to broad-band incoherent optical 
radiation (0.38 to 3 microM). International Commission on Non-Ionizing Radia-
tion Protection. Health Phys. 73: 539–554. 
Ito S., Rachinger W., Stepp H., Reulen H.J., and Stummer W. (2005): Oedema 
formation in experimental photo-irradiation therapy of brain tumours using 5-
ALA. Acta Neurochir.(Wien.) 147: 57–65. 
Jacques S.L. (1996): Origins of tissue optical properties in the UVA, Visible, and 
NIR regions. In: OSA Topics in Optics and Photonics, Advances in Optical Imag-
ing and Photon Migration, edited by R.R.Alfano and J.G.Fujimoto, pp. 364–369. 
Optical Society of America, Washington DC. 
Jacques S.L. (1998): Skin Optics Summary. 
http://omlc.ogi.edu/news/jan98/skinoptics.html, Oregon Medical Laser Center, 
Providence St.Vincent Medical Center, USA. 
Jeffes E.W. (2002): Levulan: the first approved topical photosensitizer for the treat-
ment of actinic keratosis. J.Dermatolog.Treat. 13 Suppl 1: S19–S23. 
Jocham D., Witjes F., Wagner S., Zeylemaker B., van M.J., Grimm M.O., Muschter 
R., Popken G., Konig F., Knuchel R., and Kurth K.H. (2005): Improved detection 
and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, 
phase III multicenter study. J.Urol. 174: 862–866. 
Juzeniene A., Juzenas P., Ma L.W., Iani V., and Moan J. (2004): Effectiveness of 
different light sources for 5-aminolevulinic acid photodynamic therapy. Lasers
Med.Sci. 19: 139–149. 
Kasche A., Luderschmidt S., Ring J., and Hein R. (2006): Photodynamic therapy 
induces less pain in patients treated with methyl aminolevulinate compared to 
aminolevulinic acid. J.Drugs Dermatol. 5: 353–356. 
Kawaoka K., Khan A.U., and Kearns D.R. (1967): Role of Singlet Excited States of 
Molecular Oxygen in the Quenching of Organic Triplet States. J.Chem.Phys. 46:
1842–1853.
REFERENCES 39
Kennedy J.C., Pottier R.H., and Pross D.C. (1990): Photodynamic therapy with 
endogenous protoporphyrin IX: basic principles and present clinical experience. J
Photochem Photobiol B 6: 143–148. 
Kloek J. and Beijersbergen v.H. (1996): Prodrugs of 5-aminolevulinic acid for 
photodynamic therapy. Photochem.Photobiol. 64: 994–1000. 
Kostron H., Fiegele T.H., and Akatuna E. (2006): Photodynamic diagnosis and 
photodynamic therapy for recurrent glioblastomas – How to Improve the results?  
6th International Symposium on Photodynamic Diagnosis and Therapy in Clinical 
Practice, October 10–14, (Abstract). 
Kreftregisteret (2006): Cancer in Norway 2004. Cancer Registry of Norway, Institute 
of Population-based Cancer Research, Norway. 
Lærum O.D., Rajewsky M.F., Schachner M., Stavrou D., Haglid K.G., and Haugen 
A. (1977): Phenotypic properties of neoplastic cell lines developed from fetal rat 
brain cells in culture after exposure to ethylnitrosourea in vivo. 
Z.Krebsforsch.Klin.Onkol.Cancer Res.Clin.Oncol. 89: 273–295. 
Lange N., Jichlinski P., Zellweger M., Forrer M., Marti A., Guillou L., Kucera P., 
Wagnieres G., and van den Bergh H. (1999): Photodetection of early human blad-
der cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced 
protoporphyrin IX: a pilot study. Br.J.Cancer 80: 185–193. 
Lilge L., Olivo M.C., Schatz S.W., MaGuire J.A., Patterson M.S., and Wilson B.C. 
(1996): The sensitivity of normal brain and intracranially implanted VX2 tumour 
to interstitial photodynamic therapy. Br.J.Cancer 73: 332–343. 
Lilge L. and Wilson B.C. (1998): Photodynamic therapy of intracranial tissues: a 
preclinical comparative study of four different photosensitizers. J.Clin.Laser 
Med.Surg. 16: 81–91. 
Lo J.S., Snow S.N., Reizner G.T., Mohs F.E., Larson P.O., and Hruza G.J. (1991): 
Metastatic basal cell carcinoma: report of twelve cases with a review of the litera-
ture. J.Am.Acad.Dermatol. 24: 715–719. 
Lobel J., MacDonald I.J., Ciesielski M.J., Barone T., Potter W.R., Pollina J., Plunkett 
R.J., Fenstermaker R.A., and Dougherty T.J. (2001): 2-[1-hexyloxyethyl]-2-
devinyl pyropheophorbide-a (HPPH) in a nude rat glioma model: implications for 
photodynamic therapy. Lasers Surg.Med. 29: 397–405. 
Lopez R.F., Lange N., Guy R., and Bentley M.V. (2004): Photodynamic therapy of 
skin cancer: controlled drug delivery of 5-ALA and its esters. Adv.Drug Deliv.Rev.
56: 77–94. 
REFERENCES40
Lui H., Hobbs L., Tope W.D., Lee P.K., Elmets C., Provost N., Chan A., Neyndorff 
H., Su X.Y., Jain H., Hamzavi I., McLean D., and Bissonnette R. (2004): Photo-
dynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red 
light-emitting diodes: two-year results evaluating tumor response and cosmetic 
outcomes. Arch.Dermatol. 140: 26–32. 
Madsen S.J., Sun C.H., Tromberg B.J., and Hirschberg H. (2001): Development of a 
novel indwelling balloon applicator for optimizing light delivery in photodynamic 
therapy. Lasers Surg.Med. 29: 406–412. 
Malik Z. and Lugaci H. (1987): Destruction of erythroleukaemic cells by photoacti-
vation of endogenous porphyrins. Br.J.Cancer 56: 589–595. 
Martin A., Tope W.D., Grevelink J.M., Starr J.C., Fewkes J.L., Flotte T.J., Deutsch 
T.F., and Anderson R.R. (1995): Lack of selectivity of protoporphyrin IX fluores-
cence for basal cell carcinoma after topical application of 5-aminolevulinic acid: 
implications for photodynamic treatment. Arch.Dermatol.Res 287: 665–674. 
Moan J. and Berg K. (1991): The photodegradation of porphyrins in cells can be 
used to estimate the lifetime of singlet oxygen. Photochem.Photobiol. 53: 549–
553.
Moan J., Ma L.W., and Iani V. (2001): On the pharmacokinetics of topically applied 
5-aminolevulinic acid and two of its esters. Int.J.Cancer 92: 139–143. 
Moore J.V., West C.M., and Whitehurst C. (1997): The biology of photodynamic 
therapy. Phys.Med.Biol. 42: 913–935. 
Morgan J., Oseroff A.R., and Cheney R.T. (2004): Expression of the peripheral 
benzodiazepine receptor is decreased in skin cancers in comparison with normal 
skin. Br.J.Dermatol. 151: 846–856. 
Muller P., Wilson B., Lilge L., Bogaars A., Hetzel F., Chen Q., Fullagar T., and 
Abrams J. (2006): Photodynamic therapy of brain tumors.  6th International Sym-
posium on Photodynamic Diagnosis and Therapy in Clinical Practice, October 
10–14, (Abstract). 
Muller P.J. and Wilson B.C. (1986): An update on the penetration depth of 630 nm 
light in normal and malignant human brain tissue in vivo. Phys.Med Biol. 31:
1295–1297.
Newell B., Bedlow A.J., Cliff S., Drysdale S.B., Stanton A.W., and Mortimer P.S. 
(2003): Comparison of the microvasculature of basal cell carcinoma and actinic 
keratosis using intravital microscopy and immunohistochemistry. Br.J.Dermatol.
149: 105–110. 
REFERENCES 41
Niedre M., Patterson M.S., and Wilson B.C. (2002): Direct near-infrared lumines-
cence detection of singlet oxygen generated by photodynamic therapy in cells in 
vitro and tissues in vivo. Photochem.Photobiol. 75: 382–391. 
Niedre M.J., Yu C.S., Patterson M.S., and Wilson B.C. (2005): Singlet oxygen 
luminescence as an in vivo photodynamic therapy dose metric: validation in nor-
mal mouse skin with topical amino-levulinic acid. Br.J.Cancer 92: 298–304. 
Obwegeser A., Jakober R., and Kostron H. (1998): Uptake and kinetics of 14C-
labelled meta-tetrahydroxyphenylchlorin and 5-aminolaevulinic acid in the C6 rat 
glioma model. Br.J.Cancer 78: 733–738. 
Olzowy B., Hundt C.S., Stocker S., Bise K., Reulen H.J., and Stummer W. (2002): 
Photoirradiation therapy of experimental malignant glioma with 5-aminolevulinic 
acid. J.Neurosurg. 97: 970–976. 
Ortonne J.P. (2002): From actinic keratosis to squamous cell carcinoma. 
Br.J.Dermatol. 146 Suppl 61: 20–23. 
Oseroff A.R., Blumenson L.R., Wilson B.D., Mang T.S., Bellnier D.A., Parsons J.C., 
Frawley N., Cooper M., Zeitouni N., and Dougherty T.J. (2006): A dose ranging 
study of photodynamic therapy with porfimer sodium (Photofrin) for treatment of 
basal cell carcinoma. Lasers Surg.Med. 38: 417–426. 
Pech O., Gossner L., May A., Rabenstein T., Vieth M., Stolte M., Berres M., and Ell 
C. (2005): Long-term results of photodynamic therapy with 5-aminolevulinic acid 
for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastro-
intest.Endosc. 62: 24–30. 
Peng Q., Evensen J.F., Rimington C., and Moan J. (1987): A comparison of different 
photosensitizing dyes with respect to uptake C3H-tumors and tissues of mice. 
Cancer Lett. 36: 1–10. 
Peng Q., Moan J., Warloe T., Iani V., Steen H.B., Bjørseth A., and Nesland J.M. 
(1996): Build-up of esterified aminolevulinic-acid-derivative-induced porphyrin 
fluorescence in normal mouse skin. J.Photochem.Photobiol.B 34: 95–96. 
Peng Q., Soler A.M., Warloe T., Nesland J.M., and Giercksky K.E. (2001): Selective 
distribution of porphyrins in thick basal cell carcinoma after topical application of 
methyl 5-aminolevulinate. J.Photochem.Photobiol.B 62: 140–145. 
Peng Q., Warloe T., Moan J., Heyerdahl H., Steen H.B., Nesland J.M., and Gierck-
sky K.E. (1995): Distribution of 5-aminolevulinic acid-induced porphyrins in 
noduloulcerative basal cell carcinoma. Photochem.Photobiol. 62: 906–913. 
REFERENCES42
Perotti C., Casas A., Fukuda H., Sacca P., and Batlle A. (2002): ALA and ALA hexyl 
ester induction of porphyrins after their systemic administration to tumour bearing 
mice. Br.J.Cancer 87: 790–795. 
Perotti C., Fukuda H., DiVenosa G., MacRobert A.J., Batlle A., and Casas A. 
(2004): Porphyrin synthesis from ALA derivatives for photodynamic therapy. In 
vitro and in vivo studies. Br.J.Cancer 90: 1660–1665. 
Preusser M., Haberler C., and Hainfellner J.A. (2006): Malignant glioma: neuropa-
thology and neurobiology. Wien.Med.Wochenschr. 156: 332–337. 
Redmond R.W. and Gamlin J.N. (1999): A compilation of singlet oxygen yields 
from biologically relevant molecules. Photochem.Photobiol. 70: 391–475. 
Robinson D.J., de Bruijn H.S., van der Veen N., Stringer M.R., Brown S.B., and Star 
W.M. (1999): Protoporphyrin IX fluorescence photobleaching during ALA-
mediated photodynamic therapy of UVB-induced tumors in hairless mouse skin. 
Photochem.Photobiol. 69: 61–70. 
Rud E., Gederaas O., Høgset A., and Berg K. (2000): 5-aminolevulinic acid, but not 
5-aminolevulinic acid esters, is transported into adenocarcinoma cells by system 
BETA transporters. Photochem.Photobiol. 71: 640–647. 
Soler A.M., Warloe T., Berner A., and Giercksky K.E. (2001): A follow-up study of 
recurrence and cosmesis in completely responding superficial and nodular basal 
cell carcinomas treated with methyl 5-aminolaevulinate-based photodynamic ther-
apy alone and with prior curettage. Br.J.Dermatol. 145: 467–471. 
Soler A.M., Warloe T., Tausjø J., and Berner A. (1999): Photodynamic therapy by 
topical aminolevulinic acid, dimethylsulphoxide and curettage in nodular basal cell 
carcinoma: a one-year follow-up study. Acta Derm.Venereol. 79: 204–206. 
Sørensen D.R., Read T.A., Porwol T., Olsen B.R., Timpl R., Sasaki T., Iversen P.O., 
Benestad H.B., Sim B.K., and Bjerkvig R. (2002): Endostatin reduces vasculariza-
tion, blood flow, and growth in a rat gliosarcoma. Neuro.-oncol. 4: 1–8. 
Star W.M. (1997): Light dosimetry in vivo. Phys.Med.Biol. 42: 763–787. 
Stummer W., Gotz C., Hassan A., Heimann A., and Kempski O. (1993): Kinetics of 
Photofrin II in perifocal brain edema. Neurosurg. 33: 1075–1081. 
Stummer W., Pichlmeier U., Meinel T., Wiestler O.D., Zanella F., and Reulen H.J. 
(2006): Fluorescence-guided surgery with 5-aminolevulinic acid for resection of 
malignant glioma: a randomised controlled multicentre phase III trial. Lancet On-
col. 7: 392–401. 
REFERENCES 43
Stummer W., Stocker S., Novotny A., Heimann A., Sauer O., Kempski O., Plesnila 
N., Wietzorrek J., and Reulen H.J. (1998): In vitro and in vivo porphyrin accumu-
lation by C6 glioma cells after exposure to 5-aminolevulinic acid. 
J.Photochem.Photobiol.B 45: 160–169. 
Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., 
Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., 
Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., 
and Mirimanoff R.O. (2005): Radiotherapy plus concomitant and adjuvant temo-
zolomide for glioblastoma. N.Engl.J.Med. 352: 987–996. 
Szeimies R.M., Karrer S., Radakovic-Fijan S., Tanew A., Calzavara-Pinton P.G., 
Zane C., Sidoroff A., Hempel M., Ulrich J., Proebstle T., Meffert H., Mulder M., 
Salomon D., Dittmar H.C., Bauer J.W., Kernland K., and Braathen L. (2002): 
Photodynamic therapy using topical methyl 5-aminolevulinate compared with 
cryotherapy for actinic keratosis: A prospective, randomized study. 
J.Am.Acad.Dermatol. 47: 258–262. 
Szeimies R.M., Morton C.A., Sidoroff A., and Braathen L.R. (2005): Photodynamic 
therapy for non-melanoma skin cancer. Acta Derm.Venereol. 85: 483–490. 
Thompson M.S., Gustafsson L., Palsson S., Bendsoe N., Stenberg M., Klinteberg 
C.A., Andersson-Engels S., and Svanberg K. (2001): Photodynamic therapy and 
diagnostic measurements of basal cell carcinomas using esterified and non-
esterified delta-aminolevulinic acid. J.of Porphyrins and Phthalocyanines 5: 147–
153.
Triesscheijn M., Baas P., Schellens J.H., and Stewart F.A. (2006a): Photodynamic 
therapy in oncology. Oncologist. 11: 1034–1044. 
Triesscheijn M., Ruevekamp M., Antonini N., Neering H., Stewart F.A., and Baas P. 
(2006b): Optimizing Meso-tetra-hydroxyphenyl-chlorin Mediated Photodynamic 
Therapy for Basal Cell Carcinoma. Photochem.Photobiol. 82: 1686–1690. 
Vakrat-Haglili Y., Weiner L., Brumfeld V., Brandis A., Salomon Y., McLlroy B., 
Wilson B.C., Pawlak A., Rozanowska M., Sarna T., and Scherz A. (2005): The 
microenvironment effect on the generation of reactive oxygen species by Pd-
bacteriopheophorbide. J.Am.Chem.Soc. 127: 6487–6497. 
van den Akker J.T., Holroyd J.A., Vernon D.I., Sterenborg H.J., and Brown S.B. 
(2003): Comparative in vitro percutaneous penetration of 5-aminolevulinic acid 
and two of its esters through excised hairless mouse skin. Lasers Surg.Med. 33:
173–181.
REFERENCES44
Vinciullo C., Elliott T., Francis D., Gebauer K., Spelman L., Nguyen R., Weightman 
W., Sheridan A., Reid C., Czarnecki D., and Murrell D. (2005): Photodynamic 
therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell car-
cinoma. Br.J.Dermatol. 152: 765–772. 
Wadhera A., Fazio M., Bricca G., and Stanton O. (2006): Metastatic basal cell 
carcinoma: a case report and literature review. How accurate is our incidence 
data? Dermatol.Online.J. 12: 7. 
Wallner K.E., Galicich J.H., Krol G., Arbit E., and Malkin M.G. (1989): Patterns of 
failure following treatment for glioblastoma multiforme and anaplastic astrocy-
toma. Int.J.Radiat.Oncol.Biol.Phys. 16: 1405–1409. 
Wang L., Jacques S.L., and Zheng L. (1995): MCML—Monte Carlo modeling of 
light transport in multi-layered tissues. Comput.Methods Programs Biomed. 47:
131–146.
Warloe T. (1995): Photodynamic therapy of human malignant tumors, A study of 
epithelial tumors of the skin, gastrointestinal tract and malignant pleural meso-
thelioma. The University of Oslo. (Ph.D. thesis). 
Weersink R.A., Forbes J., Bisland S., Trachtenberg J., Elhilali M., Brun P.H., and 
Wilson B.C. (2005): Assessment of cutaneous photosensitivity of TOOKAD 
(WST09) in preclinical animal models and in patients. Photochem.Photobiol. 81:
106–113.
Weishaupt K.R., Gomer C.J., and Dougherty T.J. (1976): Identification of singlet 
oxygen as the cytotoxic agent in photoinactivation of a murine tumor. Cancer Res.
36: 2326–2329. 
Wennberg A.M., Larkö O., Lönnroth P., Larson G., and Krogstad A.L. (2000): 
Delta-aminolevulinic acid in superficial basal cell carcinomas and normal skin—a 
microdialysis and perfusion study. Clin.Exp.Dermatol. 25: 317–322. 
Wiegell S.R., Stender I.M., Na R., and Wulf H.C. (2003): Pain associated with 
photodynamic therapy using 5-aminolevulinic acid or 5-aminolevulinic acid me-
thylester on tape-stripped normal skin. Arch.Dermatol. 139: 1173–1177. 
Wiegell S.R. and Wulf H.C. (2006a): Photodynamic therapy of acne vulgaris using 
5-aminolevulinic acid versus methyl aminolevulinate. J.Am.Acad.Dermatol. 54:
647–651.
Wiegell S.R. and Wulf H.C. (2006b): Photodynamic therapy of acne vulgaris using 
methyl aminolaevulinate: a blinded, randomized, controlled trial. Br.J.Dermatol.
154: 969–976. 
REFERENCES 45
Wilson B.C., Patterson M.S., and Lilge L. (1997): Implicit and explicit dosimetry in 
photodynamic therapy: a new paradigm. Lasers Med.Sci. 12: 182–199. 
Wolf P. and Kerl H. (1995): Photodynamic therapy with 5-aminolevulinic acid: a 
promising concept for the treatment of cutaneous tumors [editorial; comment]. 
Dermatology 190: 183–185. 
Zhu T.C., Dimofte A., Finlay J.C., Stripp D., Busch T., Miles J., Whittington R., 
Malkowicz S.B., Tochner Z., Glatstein E., and Hahn S.M. (2005): Optical proper-
ties of human prostate at 732 nm measured in mediated photodynamic therapy. 
Photochem.Photobiol. 81: 96–105. 
